Captures sustained GSK price trends driven by pipeline developments and sector rotation
| Strategy Type | Trend Following / Moving Average Crossover |
| Market Outlook | Captures sustained GSK price trends driven by pipeline developments and sector rotation |
| Risk Profile | Moderate Risk (Defensive healthcare stock with pipeline event risk) |
| Reward Profile | 1.5:1 to 2.5:1 Risk-Reward in trending conditions |
| Time Horizon | Medium-term (Weeks to Months) |
| Iv Environment | Works best in trending markets; struggles during sideways consolidation |
| Breakeven | Entry Price ± Spread + Commission |
| Primary Instruments | GSK.L (London LSE in GBP), GSK (NYSE ADR in USD) |
| Mas Compliance | MAS regulated brokers required; foreign stock trading permitted |
| Trading Hours | London: 4 PM - 12:30 AM SGT; US: 9:30 PM - 4:00 AM SGT |
| Contract Size | Shares or CFDs; fractional shares available at some brokers |
| Settlement | T+2 for shares; instant for CFDs |
| Tax Treatment | No capital gains tax for individuals in Singapore; dividends subject to withholding (UK 0%) |
| Stamp Duty | UK stamp duty 0.5% on GSK.L purchases; no stamp on US ADR |
| Cdp Account | Not required for foreign stocks; custody with broker |
| Singapore Relevance | GSK provides defensive healthcare exposure; pharmaceutical sector uncorrelated with local markets |
9/21 EMA is a classic combination balancing responsiveness and smoothness. 9 EMA responds to recent moves, 21 EMA shows the underlying trend. This combination works well for GSK's moderate volatility.
The 50 EMA acts as a trend filter. Only take long signals when price is above 50 EMA (uptrend). This filters out false signals that go against the bigger trend.
Wait for daily close with 9 EMA above 21 EMA. Enter on next bar open. Alternatively, wait for pullback to 21 EMA for better entry price. Always check 50 EMA trend filter.
Exit on death cross (9 EMA below 21 EMA), or if price closes below 21 EMA, or if stop hit (2× ATR), or on time stop (60 days max). Take partials on extended moves.
Healthcare demand is stable regardless of economy - people still need medicines. GSK has lower beta (0.5-0.7), meaning it's less volatile than the market and often outperforms during downturns.
Major pipeline events (Phase 3 data, FDA decisions) can gap price significantly. Avoid entering 5 days before known events. Wait for post-event EMA confirmation. Positive news + bullish EMA = add.
During risk-off periods, investors rotate to defensive sectors like healthcare. This creates tailwind for GSK. Check FTSE Healthcare trend - sector bullish + GSK bullish = high conviction.
Weekly 9/21 EMA shows major trend. Daily provides entry timing. Best signals: weekly bullish + daily golden cross. Avoid daily longs when weekly is bearish.
In uptrend, yes - hold through to capture ~4% annual dividend. Stock drops by dividend amount on ex-date but typically recovers in uptrend. Post ex-date pullback can be good entry.
Use relative strength. GSK better for income (higher dividend) and defensive positioning. AZN for growth exposure. If both have EMA signals, choose the one with higher/rising RS.
k = 2/(Period+1). EMA = (Close × k) + (Previous_EMA × (1-k)). For 9 EMA: k = 0.20. For 21 EMA: k = 0.091. Golden_Cross = EMA_9 > EMA_21 AND EMA_9[1] <= EMA_21[1].
Buy calls on golden cross for defined risk. Covered calls in sideways generate income. Bull call spreads reduce cost. Cash-secured puts to enter at lower price. Protective puts on death cross.
GSK.L in GBP, ADR in USD. Singapore investors face currency risk either way. Bullish GBP: prefer GSK.L. Bullish USD: prefer ADR. Small positions: accept risk. Large: consider hedging.
Government pricing pressure affects entire pharma sector. Favorable environment = full size on signals. Major policy change = wait for clarity. Monitor US and UK healthcare policy regularly.
Max 5% GSK, 15% healthcare sector, 10% pharma combined. GSK provides defensive balance and dividend income. Low correlation with banks/cyclicals offers diversification.
Full guided lessons, quizzes, and a complete strategy library for the Singapore market. One-time purchase. No subscription, ever.
Get Singapore access →